Innovation on the Rise New Partnering Paradigms & Pathways

Ninth Annual

Co-Sponsors

Wednesday, May 8, 2019 The Palace at Somerset Park, Somerset, NJ www.BioNJ.org WELCOME

Ninth Annual

Welcome to BioNJ’s 2019 BioPartnering Conference,

On behalf of BioNJ, J.P. Morgan and Johnson & Johnson Innovation, it is our honor to welcome you to the Ninth Annual BioPartnering Conference, “Innovation on the Rise: New Partnering Paradigms & Pathways.”

We are excited to bring together biopharmaceutical executives, investors, academic collaborators and business development professionals from the Northeast to Mid- Atlantic for a day of 1:1 partnering meetings, in-depth plenary sessions, exhibits and posters, networking and company presentations. Today is about growing the ecosystem and partnering to bolster medical innovation.

The program is designed to foster productive partnerships, create fruitful opportunities and support the valuable work you do to bring hope to Patients around the world.

There are many people to thank for their contributions in getting us to this important day, beginning with our speakers, judges, exhibitors, supporting partners and generous sponsors who have supported this initiative in exceptional ways.

We are grateful to our panel of industry experts who are leading the plenary discussions. Additionally, we are appreciative of the world-renowned regional institutions exhibiting today, reminding us of the critical role industry and academic collaboration plays in driving innovation. And finally, a special thank you to the BioPartnering Conference Planning Team Members who have given so freely of their time and talent during the last several months to transform a vision from concept to reality.

We hope you come away from today’s conference with new collaborations, partnerships and inspiration that will lead to future innovation. Thank you for being here.

Because Patients Can’t Wait®,

Debbie Hart Alma DeMetropolis, CFA, CFP® William N. Hait, M.D., Ph.D. President and CEO Managing Director Global Head, Johnson & BioNJ Market Manager Johnson External Innovation President, New Jersey Market Leadership Team J.P. Morgan Private Bank

1 CONFERENCE AGENDA CONFERENCE AGENDA

Ninth Annual

12:30 p.m.-1:20 p.m. NETWORKING LUNCHEON

1:20 p.m.-1:50 p.m. FIRESIDE CHAT: PAVING PATHWAYS TO A “WORLD WITHOUT DISEASE” William N. Hait, M.D., Ph.D., Global Head, Co-Sponsors Johnson & Johnson External Innovation IN CONVERSATION WITH: Debbie Hart, President & CEO, BioNJ

2:00 p.m.-3:30 p.m. COMPANY PRESENTATIONS AND PARTNERING Wednesday, May 8, 2019 MEETINGS

INSTITUTION/START-UP TRACK: INVESTOR PANEL REGISTRATION & NETWORKING BREAKFAST 2:00 p.m.-3:30 p.m. 7:30 a.m.-8:40 a.m. DISCUSSION AND PITCH PRESENTATIONS (SALON 4)

8:40 a.m.-9:00 a.m. WELCOME & OPENING REMARKS Sonia Gulati, Ph.D., Executive in Residence Kairos Ventures Debbie Hart, President & CEO, BioNJ Edward Rosen, Founder, Glendevon Life Sciences 9:00 a.m.-9:30 a.m. AN INDUSTRY UPDATE AND TRENDS OVERVIEW Donald Very, Ph.D., Chief Technical Analyst, Robert Huffines, Global Chairman, Investment Devices and Diagnostics, Velocity Fund Banking, J.P. Morgan Management, LLC Michael Wiley, Vice President, New Jersey Health 9:30 a.m.-10:20 a.m. DIVERSE NEW PATHWAYS TO STRATEGIC Foundation/Foundation Venture Capital Group, LLC PARTNERING MODERATED BY: Chip Baird, Chief Financial Officer, bluebird bio Michal Preminger, Ph.D., MBA, Head, Johnson & Johnson Innovation, East North America Matthew Roden, Ph.D., Head, Strategic Corporate Development & Global Business Development NETWORKING, COMPANY PRESENTATIONS Q&A, Assessment, Bristol-Myers Squibb 3:30 p.m.-4:00 p.m. PARTNERING MEETINGS AND EXHIBITS Debi Watson, Head, Oncology Business Development Group, Johnson & Johnson 4:00 p.m.-4:30 p.m. FIRESIDE CHAT: PARTNERING IMPERATIVES AND Innovation, Janssen Business Development NAVIGATING TO COMMERCIALIZATION MODERATED BY: Brian Flood, Managing Director, J.P. Morgan John Whittaker, MBA, Executive Director Healthcare Investment Banking, J.P. Morgan Patrik Ringblom, Global Commercial Strategy Leader for Oncology, Janssen Global Services 10:30 a.m.-12:00 p.m. COMPANY PRESENTATIONS AND PARTNERING MEETINGS 4:30 p.m. CLOSING REMARKS Debbie Hart, President & CEO, BioNJ 12:00 p.m.-12:30 p.m. NETWORKING, COMPANY PRESENTATIONS Q&A, PARTNERING MEETINGS AND EXHIBITS www.BioNJ.org

2 3 INDUSTRY SHOWCASE INSTITUTION EXHIBITORS

Columbia University Maria Rahmany, Ph.D., MBA, Business Development Columbia Technology Ventures [email protected] www.andersentax.com www.bezwadabiomedical.com www.bio.org Coriell Institute for Medical Research Ellen M. Kelly, Ph.D., Program Director [email protected]

Hackensack Meridian Health Sandra Elliott, Vice President, Life Sciences & Innovation www.cannoncassidy.com www.connorstrong.com www.coretelligent.com Physician Enterprise Division [email protected]

Johns Hopkins University Hassan Naqvi, Director, Corporate Partnerships [email protected]

New Jersey Institute of Technology www.fishersci.com www.friedmanllp.com www.eisneramper.com Haro Hartounian, Executive Director Biotechnology and Pharmaceutical Innovation, iLab Development [email protected]

New York University Abram Goldfinger, Executive Director www.ipmcinc.com www.jpmorgan.com www.jnjinnovation.com Industrial Liaison/Technology Transfer [email protected]

Princeton University Dean R. Edelman, Corporate Engagement & Foundation Relations [email protected]

www.labowl.com www.leaderstrong.com www.nucleusnetwork.com.au Rutgers, The State University of New Jersey Vincent Smeraglia, Executive Director of Strategic Alliances Translational Sciences [email protected]

Rowan University Jeanne Nevelos, Managing Director, Rowan Innovations www.rsmus.com www.scientist.com www.scisafe.com [email protected]

Stevens Institute of Technology David Zimmerman, Director of Technology Commercialization [email protected]

www.sharevault.com www.springernature.com www.unifirst.com University of Pennsylvania Viviane Martin, Ph.D., Director, Perelman School of Medicine Penn Center for Innovation [email protected]

The Wistar Institute www.withum.com Heather A. Steinman, Ph.D., MBA, Vice President Business Development & Executive Director, Technology Transfer The Wistar Institute [email protected]

4 5 MAP | 1st FLOOR MAP | 2nd FLOOR

6 7 SPEAKERS SPEAKERS

Welcome & Opening Remarks Matthew Roden, Ph.D. Head, Strategic Corporate Development & Global Business Debbie Hart Development Assessment, Bristol-Myers Squibb (BMS) President & CEO, BioNJ At BMS, Dr. Roden oversees the Global Mergers & Acquisition team Ms. Hart worked alongside NJ’s biotechnology industry leaders to establish accountable for acquisitions, structured transactions, strategic equity BioNJ in 1994. She was recently named by Governor Murphy to the NJ investing and divestitures, as well as leading Business Development Search Commission on Science, Innovation and Technology; as co-chair of the NJ and Evaluation activities for all therapeutic categories. Prior to joining BMS, he was Head Higher Education Strategic Plan Research, Innovation and Talent Working of Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Group; and the NJ Commission on Higher Education and Business Partnership. Ms. Hart Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an served as chair of the NJ Biotechnology Task Force, is a founding board member and officer of Associate at Credit Suisse First Boston. Dr. Roden serves on the BioNJ Board of Trustees. OpportunityNJ and serves on the boards of the NJ Chamber of Commerce and Choose New Jersey. Ms. Hart was named one of the world’s 100 Most Influential People in Biotechnology by Debi Watson Scientific American Worldview. Head, Oncology Business Development Group Johnson & Johnson Innovation, Janssen Business Development Alma DeMetropolis, CFA, CFP® Managing Director, Market Manager In her role, Ms. Watson leads Business Development Strategy in President, New Jersey Market Leadership Team coordination with Oncology R&D and Commercial Leadership. She is J.P. Morgan Private Bank responsible for all aspects of licensing, search and evaluation, M&A and alliance management for the Janssen Oncology Therapeutic area. Under Ms. Watson’s Ms. DeMetropolis provides executive leadership across our firm’s lines of leadership, the oncology team has executed several important transactions, including the business as well as both community and employment engagement. She recent BCMA CAR-T/Legend deal, niraparib/TESARO, Imetelstat/Geron and two deals with has been advising families, endowments and foundations on a broad range of wealth matters MacroGenics. With her guidance, the oncology team manages several significant alliances, and managing investment portfolios for over 20 years and joined J.P. Morgan in 1992. Ms. including the Ibrutinib alliance with Pharmacyclics/Abbie and Daratumumab with Genmab. DeMetropolis is on the boards of the Liberty Science Center, the Community Food Bank of New Jersey, New Jersey Performing Arts Center, SciTech Scity and Nature Conservancy NJ Advisory Council. John Whittaker, MBA Executive Director, Healthcare Investment Banking, J.P. Morgan An Industry Update and Trends Overview Mr. Whittaker is a Executive Director in the Healthcare Banking Group at J.P. Morgan. He focuses primarily on life sciences clients in the pharmaceutical Robert Huffines and biotechnology space, including animal health companies. Mr. Whittaker Global Chairman, Investment Banking, J.P. Morgan has worked on numerous M&A assignments, IPOs and equity follow-on Mr. Huffines joined J.P. Morgan in 1991. He joined in the Mergers and offerings as well as investment-grade debt offerings. M&A assignments include both buy-side Acquisitions Group, where he was healthcare focused. From 2002 – 2010, and sell-side transactions with public and private companies. Currently based in New York, he Mr. Huffines was Co-Head of the Global Healthcare Investment Banking spent several years working with the JPM Healthcare team in London covering European clients. Group. In 2011, he was promoted to Vice Chairman to deepen the firm’s relationships with significant clients. In 2017, Mr. Huffines was added to the Global Banking Management Team and named Co-Chair of the Global Strategic Advisory Council. Prior to Fireside Chat: Paving Pathways to a “World Without joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons. Disease”

Diverse New Pathways to Strategic Partnering William N. Hait, M.D., Ph.D. Global Head, Johnson & Johnson External Innovation Chip Baird Dr. Hait leads the external sourcing and creation of transformational Chief Financial Officer, bluebird bio innovation to help Johnson & Johnson achieve its mission to change the Mr. Baird joined bluebird bio in February of 2019. He has over 20 years of trajectory of health for humanity. He works on building an enterprise- financial and strategic planning experience in the biopharmaceutical sector. wide external R&D pipeline, creating innovative solutions that utilize Prior to bluebird bio, he served as CFO of Amicus Therapeutics for seven J&J’s excellence in pharmaceuticals, medical devices and consumer products. His team years and spent 10 years as CFO of PTC Therapeutics with responsibility strives to identify disruptive technologies and cutting-edge early innovations in disease for all areas of finance, investor and public relations, human resources, facilities and project areas of emphasis at J&J, to eliminate disease through prevention, interception and cures. management. Mr. Baird also worked in the life sciences practice at L.E.K. Consulting and at Before joining J&J, Dr. Hait was the founding Director of The Rutgers Cancer Institute of First Union National Bank. He currently serves as a Director of Axcella Health. New Jersey.

8 9 SPEAKERS SPEAKERS

Investor Panel Discussion Michael Wiley Vice President, New Jersey Health Foundation/Foundation Venture Sonia Gulati, Ph.D. Capital Group, LLC Executive in Residence, Kairos Ventures The New Jersey Health Foundation and its affiliate, Foundation Venture Dr. Gulati has a broad background in life sciences venture capital, Capital Group, LLC, provide funding and/or pre-seed investments for strategy consulting and basic science research. As an EIR, she works health-related projects and start-up companies founded by researchers closely with founding scientists and their teams to develop and execute at the following affiliated organizations: Kessler Foundation, New Jersey Institute of a commercialization strategy in order to help companies reach key Technology, Princeton University, Rowan University, Rutgers University and Stevens commercial milestones. Prior to joining Kairos Ventures, Dr. Gulati was an Assistant Institute of Technology. Mr. Wiley assists the Foundation Venture Capital Group’s health- Director at New York Ventures. Before New York Ventures, she worked at a boutique related portfolio companies by providing funding and assisting with the various strategic, healthcare consultancy where she helped biotechnology and pharmaceutical companies operational and back office management issues associated with developing and growing meet their commercial development goals by informing their product launch and life cycle early stage health-related companies. management strategies.

Michal Preminger, Ph.D., MBA Fireside Chat: Partnering Imperatives and Navigating Head, Johnson & Johnson Innovation, East North America to Commercialization Dr. Preminger oversees a portfolio of co-investments and collaborations spanning across pharmaceutical, consumer health and medical devices and Brian Flood oversees the construction, prioritization and advancement of the External Managing Director, J.P. Morgan R&D portfolio for the Boston Innovation Center. She previously served as the Executive Director of Harvard University’s Office of Technology Development, Harvard Mr. Flood provides advice on a wide range of investment solutions for Medical School site, where she negotiated license agreements with major biopharma, life a diverse client base including ultra-high net worth families, financial sciences, food and cosmetics companies to create a revenue-generating product pipeline. Prior principals, private foundations and endowments. His responsibilities to Harvard, Dr. Preminger held a number of business and technology development positions at include advising clients on asset allocation and constructing investment Compugen. portfolios utilizing both traditional and alternative investments. Mr. Flood joined J.P. Morgan in 1998 as a Fixed Income Product Specialist focusing on the tax exempt bond market. He later joined the Northeast business as a sales trader, concentrating on brokerage solutions Edward Rosen for private clients in the New York Metropolitan Area. Founder, Glendevon Life Sciences Mr. Rosen is a serial entrepreneur with a foundation of success in multinational drug, device and diagnostic companies. He is the Founder and Patrik Ringblom Managing Partner of Glendevon Life Sciences LLC, an early stage fund Global Commercial Strategy Leader for Oncology, Janssen Global and accelerator bridging academia and Series A funding. Mr. Rosen is also Services currently an Executive in Residence for the Technology Ventures Group at Columbia University. He was the founding CEO, President and Director of Elucida Oncology, Inc. and has a passion Mr. Ringblom is responsible for setting and executing the oncology towards driving companies and the people within to fulfill their true potential. strategy, building disease area strongholds and business development. He has direct responsibility for a fully integrated team, including dedicated resources in strategic marketing, strategic analytics, market access, medical Donald Very, Ph.D. affairs and business development. Mr. Ringblom played an important part rolling out the Chief Technical Analyst, Devices and Diagnostics 2020 Roadmap and secured that the Disease Area Stronghold model became a success. Velocity Fund Management, LLC During his time in oncology, Janssen has become the 4th largest oncology company (previously 15th largest) with a best-in-class portfolio for the future of Patients with With over 30 years of diagnostic and pharmaceutical assay development prostate, lung and hematology cancers. and performance qualification experience in such diverse clinical areas as oncology, infectious disease and metabolic disease, Dr. Very has extensive experience in all phases of diagnostic assay research, development, performance validation, clinical trial design and implementation and regulatory approval. In addition to his position at Velocity Fund Management, LLC, Dr. Very is also President, CEO and Founder of Naviter Bioanalytics, LLC, a private consulting firm specializing in biomedical technology evaluation, bioanalytical method development, performance qualification and regulatory approval.

10 11 THANK YOU TO OUR SPONSORS THANK YOU TO OUR SPONSORS

Partnering Professionals Breakfast Sponsor Institution Alley Sponsors

Company Presentation Sponsors Exhibit Sponsors

Partnering Area Sponsors

12 13 SPONSOR PROFILES SPONSOR PROFILES

Ashton Tweed Conner Strong Ashton Tweed’s executive talent bank provides your company highly experienced executives Conner Strong is a leader in risk management, insurance and employee benefits within the life and life sciences industry experts ready for interim or permanent placement. When you partner sciences arena. Our dedicated team of professionals exclusively services the complex insurance with Ashton Tweed, you benefit from our deep understanding of the life sciences market and needs of the life sciences community on a national and global scale. We know science, and just connection to the pharmaceutical, biotechnology, diagnostic and medical device sectors. as importantly, we know your process. Our approach is part experience, part process and all Whether you are or you require executive or management talent — interim, permanent or partnership. interim to hire — Ashton Tweed can meet your specialized retained search needs. Coretelligent Andersen Tax Coretelligent is a leading provider of comprehensive managed IT, cyberecurity and cloud Andersen Tax delivers a full range of value-added and cost effective services to our clients. services, enabling organizations to seamlessly power and successfully grow their businesses. We take the time to understand the intricacies of each individual and business so that we can Founded in 2006 and led by world-class experts, Coretelligent’s key services — managed tailor our service to each client’s unique situation. Andersen Tax is the founding member of IT, cybersecurity and cloud solutions — are relied on by top-tier organizations in the financial Andersen Global, an international association of legally separate, independent member firms services, life sciences, legal and technology industries. Coretelligent’s team is recognized as with more than 4,000 professionals worldwide, over 500 global Partners, and a presence in leaders by CRN, Inc., MSPmentor and the U.S. Chamber of Commerce. over 138 locations through its member firms and collaborating firms. EisnerAmper Amicus Therapeutics EisnerAmper’s Life Sciences Practice professionals have the expertise, resources and relationships Amicus Therapeutics is a global, Patient-dedicated biotechnology company focused on to assist both public and private life sciences companies bridge the gap between business and discovering, developing and delivering novel high-quality medicines for people living with rare science. In addition to the traditional tax and accounting services, EisnerAmper also assists our metabolic diseases. life sciences clients with services such as internationalization, cybersecurity, process automation, SOX and more. BIO Friedman LLP BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and Friedman LLP has been serving the accounting, tax and business consulting needs of public and in more than 30 other nations. BIO members are involved in the research and development of private companies since 1924. Our Life Sciences Services Practice enables life sciences companies innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also and their bio-entrepreneurs, at every stage of their life cycle, to do what they do best: innovate produces the BIO International Convention, the world’s largest gathering of the biotechnology and work creatively. As that occurs, you can be assured that the complex and nuanced accounting, industry, along with industry-leading investor and partnering meetings held around the world. reporting and tax compliance issues associated with capital, financing, licensing and other Mark your calendar for the convention in Philadelphia, PA June 3-6, 2019. collaborative arrangements are effectively managed.

Bezwada Biomedical Haug Partners Bezwada Biomedical is an innovation driven start-up company catering to the unmet needs Haug Partners is a full-service, national law firm that provides integrated multidisciplinary legal of the biomaterial community and medical device industry. With our state-of-the-art research services for life sciences and technology companies. Our service offerings include: (i) Antitrust and development facilities in the U.S. and India, combined with our platform technologies Litigation and Counseling; (ii) Commercial Litigation and Strategic Counseling; (iii) Due Diligence; derived from a family of novel and proprietary biodegradable polymeric biomaterials, we (iv) FDA Compliance and Counseling; (v) Intellectual Property Enforcement; (vi) Intellectual Property work with and for our customers to translate their demands into high-quality products for a Procurement and Strategy; (vii) International Trade Commission; (viii) Investigations, Compliance and wide range of medical device and therapeutic applications in a cost effective manner. Risk Mitigation Services; (ix) Licensing and Transactions and (x) Trademarks and Unfair Competition. Bristol-Myers Squibb Integrated Project Management Company, Inc. (IPM) Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help Patients prevail over serious diseases. Our Integrated Project Management Company, Inc. (IPM) is a business consulting firm focused medicines are helping millions of people around the world in their fight against serious disease. on planning and implementing strategically critical initiatives. For more than 30 years, IPM has managed thousands of projects for more than 150 biotech, pharmaceutical and medical technology CannonCassidy companies, as well as in the healthcare, consumer products and industrial sectors. Consultants work with the cross-functional experts of our clients, which range from start-ups to some of the world’s CannonCassidy is a global naming consultancy providing strategic and creative branding largest firms. Headquartered in Chicago, IPM has regional offices in Parsippany, Boston, St. Louis, services to the pharmaceutical, biotechnology, medical device, consumer and industrial sectors. Los Angeles, San Francisco and Minneapolis. Services include brand name/trademark development, USAN/INN name development, clinical trial naming, platform technology naming, legal and regulatory screening, POCA analysis, name validation research, linguistic analysis and visual identity/logo development. FDA, EMA, Health Canada Regulatory Expertise.

14 15 SPONSOR PROFILES SPONSOR PROFILES

Johnson & Johnson Innovation New Jersey Health Foundation Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide New Jersey Health Foundation supports health-related research and education programs in and forming collaborations between entrepreneurs and Johnson & Johnson’s global healthcare New Jersey through its Research Grant Program, Innovation Grant Program and its affiliate, businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging Foundation Venture Capital Group, which provides pre-seed investments to help health-related companies with one-stop access to science and technology experts who can facilitate start-up companies established by researchers at Kessler Foundation, New Jersey Institute of collaborations across the pharmaceutical, medical device and consumer companies of Johnson Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of & Johnson. We connect with innovators through our regional Innovation Centers; Johnson & Technology advance toward commercialization. Johnson Innovation – JLABS; Johnson & Johnson Innovation – JJDC, Inc.; and our Janssen business development teams. Nucleus Network Nucleus Network (NN) is Australia’s only multi-site dedicated Phase I CRO located in J.P. Morgan Melbourne (80 beds) and Brisbane (62 beds). The facilities are strategically co-located within the Alfred Hospital in Melbourne and the Royal Brisbane and Women’s Hospital in Brisbane. J.P. Morgan Life Sciences bankers are dedicated to delivering financial solutions tailored to This provides NN with access to a combined population of 7.5 million people. Since 2004, your needs. From early-stage startups to multinational corporations, we understand the unique NN has conducted over 750 studies, with 90% of clients being overseas pharmaceutical and challenges life science companies face at every stage of their life cycle. Our national footprint biotech companies. NN runs approximately 70 studies per year, with around 30 of these being enables us to provide access to vital industry networks and leverage firm-wide expertise while true first-in-human studies. helping guide your company as it navigates the regulatory environment and FDA approval process. Pfizer Lab Owl™ At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value Lab Owl™ is a flexible and fully integrated bioreactor control system for cell culture and in the discovery, development and manufacture of healthcare products. Our global portfolio fermentation applications. Available in a variety of form factors, Lab OwlTM features an easy- includes medicines and vaccines as well as many of the world’s best-known consumer health to-use interface that has been leveraged in applications ranging from benchtop bioreactors in products. Every day, Pfizer colleagues work across developed and emerging markets to development labs through pilot plants and manufacturing. advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to LeaderStrong support and expand access to reliable, affordable healthcare around the world. LeaderStrong is a boutique New Jersey-based leadership consulting, strategic advisory and executive coaching firm on a mission to dramatically increase the leadership impact of the high- Princeton Innovation Center BioLabs tech and biotech clients we serve in the New York to Philadelphia corridor. LeaderStrong helps clients increase the velocity and relevance of their organizations through our thought leadership Princeton Innovation Center BioLabs is a vibrant meeting place for members of the New in our proven and proprietary methodologies. Our highly tailored leadership programs enable Jersey science community. The new center for science entrepreneurs was launched in our clients to get the hard hitting business results they desire. partnership with Princeton University. The Center includes fully supported and equipped dedicated science co-working, meeting and event space for high potential early stage McCarter & English companies. There is wet lab space for chemical, biological and pharmaceutical development and dry lab space for engineering development. Princeton Innovation Center BioLabs is part of McCarter & English delivers strategic legal counsel to life sciences clients in every phase of BioLabs’ network of facilities that is helping to change the way science companies are created. their life cycle. Our team of 130 intellectual property lawyers and professionals — including 30+ Ph.D.s in the disciplines that drive the industry — regularly collaborate to advise RSM US LLP enterprises in IP portfolio management, transactions and dispute resolution. From the world’s largest pharmaceutical and medical device companies to research universities, leading-edge RSM US LLP is the U.S. member of RSM International, a global network of independent audit, start-ups and the investors who fund them, our clients trust us to bring the innovative solutions tax and consulting firms with more than 41,000 people in 116 countries. RSM’s purpose is to required to assure their success in this highly complex marketplace. deliver the power of being understood to our clients, colleagues and communities through world-class audit, tax and consulting services focused on middle market businesses. We have advised life sciences companies in all stages; assisting during scientific discovery, development, Merck & Co. financing, regulatory approval, intellectual property monetization, IPOs, structuring and M&As. Merck & Co. has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. With more than 100 significant business development Scientist.com transactions since 2017, our team has experience working on collaborations from discovery Scientist.com is the world’s largest marketplace for outsourced research services. For over a decade through clinical-stage programs. We believe that by working together we can play a major Scientist.com has connected global research organizations with commercial research organizations role in transforming global healthcare. Together we can invent for life. Learn more at merck. (CROs) to simplify research outsourcing. The marketplace is a source-to-pay platform that saves com/licensing. researchers time, reduces costs, provides access to the latest research innovations and ensures regulatory compliance.

16 17 SPONSOR PROFILES THANK YOU TO OUR SPONSORS

SciSafe SciSafe offers dedicated pharmaceutical, biological, and consumer products sample management services in its fully cGMP compliant state-of-the-art facilities. SciSafe stores over 30,000,000 of our client’s most precious and valuable samples in over 300 freezers and walk in rooms. Our state-of-the-art facilities are located throughout the U.S. We are currently expanding to service the ever-increasing global market. We offer everything from cold chain delivery to cold storage in our New Jersey and Massachusetts facilities.

ShareVault ShareVault’s secure document sharing solution enables organizations to protect, manage and share confidential information. Endorsed by BIO and 49 affiliates, ShareVault’s life sciences functions have been used to support multiple applications, including business transaction due diligence for M & A, in/out licensing, IPO, asset sale, fundraising, technology transfer and buy side deals; confidential information sharing for partnering, alliance collaboration, CRO/CMO collaboration, board members, investors, consultants, vendors, attorneys; secure storage and efficient viewing of regulatory eCTD submissions and electronic trial master file (eTMF) sharing and review and consolidation of document silos using connectors to SharePoint/Office365, Box, Dropbox and Docusign e-signature.

Springer Nature Springer Nature is one of the world’s leading global research, educational and professional publishers, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world’s largest academic book publisher and numbers almost 13,000 staff in over 50 countries.

Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $23 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve Patient diagnostics, deliver medicines to market and increase laboratory productivity.

Toppan Merrill Toppan Merrill is a leader in financial printing and communication solutions and has been a pioneer and trusted partner to the financial, legal and corporate communities for five decades, providing secure, innovative solutions to complex content and communications requirements. Through proactive partnerships, unparalleled expertise, continuous innovation and unmatched service, Toppan Merrill delivers a hassle-free experience for mission-critical content for capital THANK YOU TO OUR SUPPORTING PARTNERS markets transactions, financial reporting and regulatory disclosure filings, and marketing and communications solutions for regulated and non-regulated industries.

Withum Withum is a forward-thinking, technology-driven advisory and accounting firm, committed to helping clients be more profitable, efficient and productive in the modern business landscape. As an independent member of HLB, the global advisory and accounting network, Withum serves businesses and individuals on a local-to-global scale. Our specialists engage with pharmaceutical, biotech and medical device companies to help navigate the business issues unique to their industry and stage of their life cycle. Our professionals provide the expert advice and innovation solutions you need to Be in a Position of StrengthSM in today’s fast-paced, tech-driven world.

18 THANK YOU TO OUR CONFERENCE CO-SPONSORS THANK YOU TO OUR PLANNING TEAM

J&J INNOVATION Kathleen Addison, Executive Director, Life Sciences, J.P. Morgan Tom Cavanaugh, President Oncology, Janssen Corey Andrews, Solutions Engineer, Merrill Datasite Charlie Knights, Director, Janssen Business Development Timothy Atkins, Partner, Pepper Hamilton, LLP Juan Ruiz, Director, U.S. New Products and Business Development, Janssen Erin Walsh, Communications Leader, Johnson & Johnson Innovation Tom Cavanaugh, President Oncology, Janssen J.P. MORGAN Dana D’Amelio, Private Banker, J.P. Morgan Kathleen Addison, Executive Director, Life Sciences Ben Davis, Vice President, Corporate Alliances, IQVIA Dana D’Amelio , Private Banker Neal Davies, Sr. Vice President, Merrill Datasite Alma DeMetropolis, CFA, CFP®, Managing Director, Market Manager, President, New Jersey Market Leadership Team, J.P. Morgan Private Bank Dean Edelman, Corporate Engagement and Foundation Relations, Princeton University Kenneth Freelund, Executive Director Sandra Elliott, Vice President, Life Sciences and Innovation, Hackensack Meridian Health

Robert Huffines, Global Chairman, Investment Banking Jean Gardner, Senior Vice President, Merrill Datasite Peter Meath, Managing Director, Industry Head Life Sciences Joshua Goldberg, Partner, Nath, Goldberg & Meyer Joseph Mellusi, CFA, Vice President Stephen Van Besien, Managing Director, Private Bank Michael Hadjiloucas, Partner-In-Charge, Corporate Tax Group, EisnerAmper, LLP John Whittaker, MBA, Executive Director, Heathcare Investment Banking Juliet Hart, Principal, Hart & Chin Associates, LLC Benjamin Hoffman, Ph.D., Senior Manager, Oncology Transactions THANK YOU TO OUR PANEL OF JUDGES Janssen Business Development Susan Kinda, Sales Director, Merrill Datasite

Michael Baran, Pfizer Jack Levitt, Co-Founder, LeaderStrong Tom Brennan, ARCH Venture Partners Beverly Lubit, Ph.D., Partner, McCarter & English, LLP Kathleen Coviello, New Jersey Economic Development Authority Scott T. Megaffin, Chief Executive Officer, Adastra Pharmaceuticals Hope D’Oyley Gay, Militia Hill Ventures Joseph Mellusi, CFA, Vice President, J.P. Morgan James Golubieski, New Jersey Health Foundation John Pennett, Partner-in-Charge, Life Sciences Group, EisnerAmper, LLP Jim Gunton, Tech Council Ventures Shahram Hejazi, BioAdvance Ravi Raghunathan, CPA, Partner, Life Science Industry Leader, CohnReznick John Prendergass, Ben Franklin Technology Partners of Southeastern PA Emilio Ragosa, Partner, DLA Piper

Gloria Rabinowitz, Golden Seeds Judith Sheft, Associate Vice President, Technology & Enterprise Development, NJIT

Jorge J. Ramirez, H.I.G. BioHealth Partners Vincent Smeraglia, Executive Director, Rutgers, The State University of New Jersey Bernie Rudnick, CapGenic Advisors Office of Research Commercialization

Robert Sawicki, Frontcourt Group Arda Ural, Ph.D., Partner, Life Sciences, Transaction Advisory Services, Ernst & Young, LLP Yaniv Sneor, MidAtlantic Bio Angels (MABA) Stephen Van Besien, Managing Director, Private Bank, J.P. Morgan Nishit Trivedi, Emerald Asset Management Erin Walsh, Communications Leader, Johnson & Johnson Innovation Michael Wells, Princeton BioPharma Capital Partners, LLC Jordan Warshafsky, Partner, Ashton Tweed, LTD Tim Whitten, Taiho Ventures, LLC David Zwally, Partner, Haug Partners, LLP Ido Zairi, Israel Biotech Fund

20 21 IMPORTANT UPCOMING BioNJ EVENTS

MAY NOVEMBER May 16: Finance Forum November 8: C-Suite Summit November TBD: Human Resource JUNE Forum June 3-6: BIO 2019 International Convention November TBD: Breakfast with BioNJ JULY DECEMBER Protecting Medical Innovation & July 18: New X2 BioCruise with December 6: Inspiring Women in NewYorkBIO STEM Conference Making a Difference Together SEPTEMBER December TBD: Legal, Compliance & Sept. 20: Manufacturing Regulatory The Value of BioNJ Membership Breakfast Briefing December TBD: Forum Legislative Sept TBD: Legal, Compliance & Holiday Reception* Regulatory Forum FEBRUARY 2020 OCTOBER February 6: Annual Dinner In these ever-changing times, it has never been more important to Oct 4: Patient Advocacy Meeting & Innovation be informed, involved and forward-looking. BioNJ Membership Summit Celebration offers the tools, resources and platforms that you and your Oct TBD: Human Resource organization need to be all three. Conference Oct TBD: Clinical Development Whether large or small, your company will benefit from BioNJ Membership through the following areas: Visit www.BioNJ.org often for calendar updates, or email [email protected] • Advocating for public policy decisions that encourage future for more information. investment in medical innovation and ensure Patient access to *Invitation only event. the therapies and cures that they need • Hosting over 35 events each year, offering networking, learning and thought leadership JOIN THE CONVERSATION

• Providing tools and resources to grow your business and Connect with BioNJ on social media help you save money on important services for the latest news on New Jersey’s • Offering unique ways to expand your visibility and build vibrant life sciences ecosystem. brand recognition Plus, learn about upcoming BioNJ events • Helping you find the talent that you need and networking opportunities. Twitter @BioNJ_Org Visit www.BioNJ.org to learn how BioNJ’s programs and www.facebook.com/BioNJ services can help your organization help Patients. Or, call www.youtube.com/BioNJvideos Kim Minton at 609-890-3185 for more information. linkedin.com/company/BioNJ

23 BioNJ TEAM

Debbie Hart President & CEO June 3-6, 2019 [email protected] Philadelphia, PA Samantha Bamberger Debbie Mennito Coordinator, Programming Operations Director, Talent Services & Events [email protected] [email protected] #BIO2019 Randi Bromberg Kim Minton Vice President, Communications and Membership Manager Marketing [email protected] [email protected] SEE YOU NEXT MONTH AT Cheri Potts Linda Brown Office Manager Vice President, Strategic Partnerships [email protected] & Programs BI 2019 IN [email protected] Dana Sacco Executive Assistant Donna Gibbons [email protected] PHILADELPHIA! Senior Vice President, Operations [email protected] Peggy Schell Talent Services and Public Policy The world’s largest global biotechnology partnering event Kristin Hassan Assistant Alliance Manager [email protected] [email protected] John Slotman 16,000+ attendees from 67 countries Erika Herbstman Vice President, Government Affairs Projected 50,000+ BIO One-on-One Partnering™ Meetings Social Media and Design Manager [email protected] [email protected] 150+ innovative education sessions 1,800+ Exhibitors showcasing the latest technology Ann Wieczkowski Denise Machado Manager, Accounting Services Discover the next generation of cutting-edge Manager, Membership Operations [email protected] products, therapies, and cures all week long. [email protected] Building B - Suite 514 Trenton, New Jersey 08619

BioNJ Visit convention.bio.org/register to register today. Whitehorse Executive Center 1255 Whitehorse-Mercerville Road Building B - Suite 514 Trenton, New Jersey 08619 Tel: 609.890.3185 Email: [email protected] 2019 BIO INTERNATIONAL CONVENTION IS HOSTED BY: www.BioNJ.org